Associations - IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Oligodendroglioma	IDH1 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH1 mutation	Sarcoma	IDH1 mutation	Sarcoma	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + BRAF V600E	Astrocytoma	IDH1 mutation + BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH1 mutation + BRAF V600E	Astrocytoma	IDH1 mutation + BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH1 mutation + NTRK3 fusion	Astrocytoma	IDH1 mutation + NTRK3 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + NTRK2 fusion	Astrocytoma	IDH1 mutation + NTRK2 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + NTRK1 fusion	Astrocytoma	IDH1 mutation + NTRK1 fusion	Astrocytoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + NTRK2 fusion	Astrocytoma	IDH1 mutation + NTRK2 fusion	Astrocytoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

Associations(160)

Associations
(160)